Beat the obstacles and accelerate early-phase research
From identifying patients to selecting efficacy endpoints, sponsors of first-in-human trials of novel oncology compounds face significant challenges. And for many sponsors, the success of the company depends heavily on the outcome of the trial.
Our white paper tracks a hypothetical drug through its development paces, exploring the many aspects you must consider when performing early-stage oncology research, including:
- Starting with a regulatory gap analysis
- Creating a development plan that details your scientific and commercial rationale and defines trial activities from Phase I to Phase IV
- Performing an eligibility review to ensure your patient population is consistent and exhibits the appropriate marker(s) for treatment